-
-
12-lead ECG obtained from a 50-year old African American man with hypertension and chest pain.
-
FDA warnings for existing drugs dominate pharmaceutical news this month.
-
Serum analysis of 45 subjects for antibodies and humoral immunity over a median of 15 years showed antiviral responses ranging from 11-19 years for tetanus-diphtheria, 50 years for varicella-zoster, and up to 200 years for measles and mumps.
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
-
These three studies published back to back in the Journal of Infectious Diseases serve to better characterize HPV infection in heterosexual men.
-
Cognitive decline after surgery requiring cardio-pulmonary bypass (CPB) may be due to cellular debris picked up by the cardiotomy suction device.
-
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
